Current Report Filing (8-k)
July 18 2017 - 4:16PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 17, 2017
APPLIED GENETIC TECHNOLOGIES CORPORATION
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-36370
|
|
59-3553710
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
14193 NW 119
th
Terrace
Suite 10
Alachua,
Florida, 32165
(Address of principal executive offices) (Zip Code)
(386) 462-2204
(Registrants telephone number, including area code)
Not Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below).
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On July 17, 2017, the compensation committee of our board of directors
approved bonus payments for fiscal year 2017 and salary changes for fiscal year 2018 for Susan Washer, our president and chief executive officer, Mark Shearman, our chief scientific officer, Stephen Potter, our vice president and chief business
officer, Michael Goldstein, our chief medical officer and Jeffrey Chulay, our executive director of clinical strategy and former chief medical officer. The following table sets forth for each individual the amount of their bonus for fiscal year
2017 and their salary for fiscal year 2018.
|
|
|
|
|
Name
|
|
Fiscal Year 2017 Bonus
|
|
Fiscal Year 2018 Salary
|
Susan Washer
|
|
$149,996.00
|
|
$501,600.00
|
Mark Shearman
|
|
$115,255.00
|
|
$388,500.00
|
Stephen Potter
|
|
$ 86,887.50
|
|
$340,930.00
|
Michael Goldstein
|
|
$ 54,390.00
|
|
$381,100.00
|
Jeffrey Chulay
|
|
$ 70,000.00
|
|
$210,000.00
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
|
|
|
APPLIED GENETIC TECHNOLOGIES CORPORATION
|
|
|
By:
|
|
/s/ Lawrence E. Bullock
|
|
|
Lawrence E. Bullock
Chief Financial
Officer
|
Date: July 18, 2017
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Apr 2023 to Apr 2024